Nasdaq:SPRB
SPRUCE BIOSCIENCES, INC.
A clinical-stage biopharma firm developing next-generation cell therapies for oncology patients.
Key Metrics
Investment Thesis
Bull Case
SPRB offers an early-mover opportunity to capitalize on breakthrough oncology treatments before market saturation occurs if clinical milestones are achieved. The company's strategic partnerships provide access to broader commercial networks and shared financial risk, potentially extending its operational runway. Investors seeking high-beta biotech exposure may view the current low cash balance as a buying opportunity ahead of potential financing events.
Bear Case
The stock is highly speculative given the absence of product revenue and a consistent history of deep net losses exceeding $50M annually over the last three years. The rapid depletion of cash reserves from nearly $96M to under $40M creates an immediate threat of insolvency if new capital cannot be raised quickly. Historical trends show deteriorating profitability with net income worsening from -$46.2M in 2022 to -$53.0M in 2024, indicating increasing operational inefficiencies.
About SPRUCE BIOSCIENCES, INC.
SPRUCE BIOSCIENCES, INC. (NASDAQ: SPRB) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapy platforms, primarily targeting oncology. The company leverages its proprietary technology to create engineered cells designed to recognize and destroy cancer cells with high specificity. Key markets include the United States and international regions where advanced cancer therapies are in high demand.
Analysis
Management Discussion
Recent financial performance highlights a challenging period characterized by widening operating losses, with net profit declining to -$53.0M in 2024 compared to -$47.9M the prior year. Despite strong R&D investments of $46.4M driving future potential, the company's cash burn rate accelerated significantly, resulting in a negative cash flow from operations of -$56.0M. The reduction in working capital changes and decrease in accounts payable suggest tight liquidity management as reserves dwindle.
Industry Overview
The global cell therapy market is experiencing rapid expansion driven by advancements in immunotherapy and personalized medicine for cancer treatment. Regulatory environments are becoming more stringent regarding safety and efficacy, which can delay product approvals and increase development costs. Competition is intensifying as large pharmaceutical companies acquire smaller biotechs or develop their own proprietary platforms.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $10.1M | $4.9M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $10.1M | $4.9M |
| Operating Expenses | $47.3M | $62.1M | $61.1M |
| Operating Income | $-47.3M | $-52.0M | $-56.2M |
| R&D | $35.2M | $49.4M | $46.4M |
| G&A | $12.1M | $12.7M | $14.6M |
| Stock-Based Comp | $3.6M | $4.6M | $5.3M |
| D&A | $74.0K | $70.0K | $46.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $420.0K | $483.0K | $307.0K |
| Pre-Tax Income | $-47.3M | $-52.0M | $-56.2M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-47.3M | $-52.0M | $-56.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-46.2M | $-47.9M | $-53.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-46.2M | $-47.9M | $-53.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $83.6M | $102.2M | $44.2M |
| Cash & Equivalents | $24.5M | $96.3M | $38.8M |
| Marketable Securities | $54.6M | $0 | — |
| Other Current Assets | $4.5M | $5.8M | $5.5M |
| Long-Term Assets | $2.0M | $1.8M | $1.0M |
| Operating Leases | $1.4M | — | — |
| LT Investments | $0 | — | — |
| Other LT Assets | $640.0K | — | — |
| Total Assets | $85.6M | $103.9M | $45.2M |
| Current Liabilities | $12.4M | $24.5M | $15.2M |
| Accounts Payable | $1.4M | $3.3M | $1.3M |
| Current Debt | $1.6M | $1.6M | $1.6M |
| Current Leases | $139.0K | $251.0K | $283.0K |
| Other Current Liab | $9.3M | $19.3M | $-283.0K |
| Long-Term Liabilities | $4.7M | $3.0M | $1.1M |
| Long-Term Debt | $3.3M | $1.7M | $124.0K |
| LT Operating Leases | $1.3M | $1.0M | $736.0K |
| Other LT Liab | $161.0K | $236.0K | $282.0K |
| Total Liabilities | $17.2M | $27.4M | $16.4M |
| Shareholders' Equity | $68.5M | $76.5M | $28.8M |
| Retained Earnings | $-149.3M | $-197.2M | $-250.3M |
| AOCI | $-558.0K | $0 | — |
| Total L&E | $85.6M | $103.9M | $45.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-46.2M | $-47.9M | $-53.0M |
| Non-Cash Adjustments | $1.9M | $-792.0K | $7.4M |
| Working Capital Changes | $2.6M | $15.4M | $-10.3M |
| Cash from Operations | $-41.7M | $-33.3M | $-56.0M |
| Capital Expenditures | $8.0K | $7.0K | $0 |
| Cash from Investing | $23.7M | $55.8M | $0 |
| Debt Issuances | $0 | — | — |
| Debt Repayments | $0 | $1.6M | $1.6M |
| Cash from Financing | $-241.0K | $49.1M | $-1.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-18.2M | $71.6M | $-57.6M |
| Beginning Cash | $43.0M | $24.7M | $96.4M |
| Ending Cash | $24.7M | $96.4M | $38.8M |
Frequently Asked Questions
How does SPRUCE BIOSCIENCES, INC. make money?
The company's revenue is currently derived from commercial partnerships and licensing agreements related to its proprietary cell therapy platforms. Financial data indicates significant investment in research and development (R&D) totaling $46.4M, with minimal cost of revenue suggesting a pre-revenue or early-stage commercial model typical of biotech firms.
What are the main risks for SPRB?
Significant dilution risk exists due to the substantial cash burn of $56.0M from operations, reducing net cash by $57.6M in the latest period. There is a high probability of failure for clinical trials given the company's status as a clinical-stage entity with no commercial revenue growth trajectory. The company faces potential liquidity constraints as its cash and equivalents dropped from $96.4M to $38.8M, raising questions about runway without further financing.
What is SPRB's competitive advantage?
The firm possesses a differentiated portfolio of engineered cell therapies that may offer superior efficacy compared to standard-of-care treatments. SPRB maintains strong intellectual property protections surrounding its unique platform technologies for cancer immunotherapy. The company has established strategic collaborations with major pharmaceutical entities to advance clinical candidates and share development costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.